What is HC Wainwright’s Forecast for MIRM FY2025 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report issued on Tuesday, January 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.19) for the year, up from their prior forecast of ($0.35). HC Wainwright has a “Buy” rating and a $102.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at $0.08 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.05) EPS.

Several other brokerages have also issued reports on MIRM. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Leerink Partners set a $100.00 price objective on Mirum Pharmaceuticals in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $102.00.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $92.32 on Thursday. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of -107.35 and a beta of 0.48. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $92.54. The business has a fifty day simple moving average of $74.59 and a 200 day simple moving average of $68.84. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same quarter last year, the company earned ($0.30) EPS. The company’s quarterly revenue was up 47.1% on a year-over-year basis.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. SG Americas Securities LLC acquired a new position in Mirum Pharmaceuticals during the 4th quarter worth $1,478,000. NorthCrest Asset Manangement LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $406,000. Tudor Investment Corp ET AL bought a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $2,027,000. CIBC Bancorp USA Inc. acquired a new position in shares of Mirum Pharmaceuticals during the third quarter valued at $315,000. Finally, PharVision Advisers LLC bought a new position in Mirum Pharmaceuticals in the third quarter valued at about $273,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.